Introduction: Obese (OB) patients are at increased risk of chronic kidney disease, but it is still unclear whether this can be attributed to obesity per se or to the associated metabolic derangements. The aim of this study was to evaluate the relative impact of obesity and metabolic syndrome (MS) on kidney disease. Methods: This is a cross-sectional study based on data obtained in the 2005–2016 cycles of the National Health and Nutrition Examination Survey. We included all adult participants with available data on body mass index, estimated glomerular filtration rate (eGFR), urine albumin to creatinine ratio (UACR), and each of the MS components. Primary outcomes were eGFR <60 mL/min, UACR ≥30 mg/g, or a combination of the two. Results: The studied population comprised 12,335 participants. OB participants without MS (OB+ MS−) were younger and more commonly female. After adjustment for potential confounders, compared with OB− MS− participants, an increased prevalence of albuminuria and reduced eGFR were present in both OB− MS+ groups and the OB+ MS+ groups, but not in the OB+ MS− groups. When each of the MS components was evaluated separately, elevated blood pressure and low high-density lipoprotein cholesterol were associated with both UACR and reduced eGFR, while elevated blood glucose and triglycerides were only associated with UACR. Waist circumference was not associated with any of the renal outcomes. Discussion/Conclusion: This large cross-sectional study suggests that MS and not obesity is associated with kidney damage and that the OB+ MS− phenotype does not seem to carry an increased risk of kidney disease.

1.
Byrne
CD
,
Targher
G
.
NAFLD as a driver of chronic kidney disease
.
J Hepatol
.
2020
;
72
(
4
):
785
801
.
2.
Eckardt
KU
,
Coresh
J
,
Devuyst
O
,
Johnson
RJ
,
Köttgen
A
,
Levey
AS
,
.
Evolving importance of kidney disease: from subspecialty to global health burden
.
Lancet
.
2013 Jul 13
;
382
(
9887
):
158
69
.
3.
Levey
AS
,
Coresh
J
,
Balk
E
,
Kausz
AT
,
Levin
A
,
Steffes
MW
,
.
National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification
.
Ann Intern Med
.
2003
;
139
(
2
):
137
47
.
4.
McLellan
F
.
Obesity rising to alarming levels around the world
.
Lancet
.
2002
;
359
(
9315
):
1412
.
5.
Jung
CH
,
Lee
MJ
,
Kang
YM
,
Hwang
JY
,
Kim
EH
,
Park
JY
,
.
The risk of chronic kidney disease in a metabolically healthy obese population
.
Kidney Int
.
2015
;
88
(
4
):
843
50
.
6.
Chang
Y
,
Ryu
S
,
Choi
Y
,
Zhang
Y
,
Cho
J
,
Kwon
MJ
,
.
Metabolically healthy obesity and development of chronic kidney disease: a cohort study
.
Ann Intern Med
.
2016
;
164
(
5
):
305
12
.
7.
Chang
AR
,
Surapaneni
A
,
Kirchner
HL
,
Young
A
,
Kramer
HJ
,
Carey
DJ
,
.
Metabolically healthy obesity and risk of kidney function decline
.
Obesity
.
2018
;
26
(
4
):
762
8
.
8.
Yun
HR
,
Kim
H
,
Park
JT
,
Chang
TI
,
Yoo
TH
,
Kang
SW
,
.
Obesity, metabolic abnormality, and progression of CKD
.
Am J Kidney Dis
.
2018
;
72
(
3
):
400
10
.
9.
Hashimoto
Y
,
Tanaka
M
,
Okada
H
,
Senmaru
T
,
Hamaguchi
M
,
Asano
M
,
.
Metabolically healthy obesity and risk of incident CKD
.
Clin J Am Soc Nephrol
.
2015
;
10
(
4
):
578
83
.
10.
Lin
L
,
Peng
K
,
Du
R
,
Huang
X
,
Lu
J
,
Xu
Y
,
.
Metabolically healthy obesity and incident chronic kidney disease: the role of systemic inflammation in a prospective study
.
Obesity
.
2017
;
25
(
3
):
634
41
.
11.
Stefansson
VTN
,
Schei
J
,
Solbu
MD
,
Jenssen
TG
,
Melsom
T
,
Eriksen
BO
.
Metabolic syndrome but not obesity measures are risk factors for accelerated age-related glomerular filtration rate decline in the general population
.
Kidney Int
.
2018
;
93
(
5
):
1183
90
.
12.
Chen
HY
,
Lu
FH
,
Chang
CJ
,
Wang
RS
,
Yang
YC
,
Chang
YF
,
.
Metabolic abnormalities, but not obesity per se, associated with chronic kidney disease in a Taiwanese population
.
Nutr Metab Cardiovasc Dis
.
2020
;
30
(
3
):
418
25
.
13.
Centers for Disease Control and Prevention
.
National Health and Nutrition Examination Survey (NHANES)
.
USA
:
Department of Health and Human Services
;
2017
. Available from: https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/default.aspx?BeginYear=2017.
14.
American Diabetes Association
.
Classification and diagnosis of diabetes: standards of medical care in diabetes‒2020
.
Diabetes Care
.
2020
;
43
(
Suppl 1
):
S14
31
.
15.
Ibargüengoitia Ochoa
F
,
Plascencia
JL
,
Flores Villalon
A
,
Zambrana Castañeda
M
.
[Acute fatty liver of pregnancy. Report of a case and review of the literature]
.
Ginecol Obstet Mex
.
2000 Dec
;
68
:
482
5
.
16.
Matthews
DR
,
Hosker
JP
,
Rudenski
AS
,
Naylor
BA
,
Treacher
DF
,
Turner
RC
.
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
.
Diabetologia
.
1985 Jul
;
28
(
7
):
412
9
.
17.
Grundy
SM
,
Brewer
HB
Jr
,
Cleeman
JI
,
Smith
SC
Jr
,
Lenfant
C
.
Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition
.
Arterioscler Thromb Vasc Biol
.
2004 Feb
;
24
(
2
):
e13
8
.
18.
Brenner
BM
,
Lawler
EV
,
Mackenzie
HS
.
The hyperfiltration theory: a paradigm shift in nephrology
.
Kidney Int
.
1996
;
49
(
6
):
1774
7
.
19.
Palaniappan
L
,
Carnethon
M
,
Fortmann
SP
.
Association between microalbuminuria and the metabolic syndrome: NHANES III
.
Am J Hypertens
.
2003
;
16
(
11
Pt 1):
952
8
.
20.
Chen
J
,
Muntner
P
,
Hamm
LL
,
Jones
DW
,
Batuman
V
,
Fonseca
V
,
.
The metabolic syndrome and chronic kidney disease in U.S. adults
.
Ann Intern Med
.
2004
;
140
(
3
):
167
74
.
21.
Thomas
G
,
Sehgal
AR
,
Kashyap
SR
,
Srinivas
TR
,
Kirwan
JP
,
Navaneethan
SD
.
Metabolic syndrome and kidney disease: a systematic review and meta-analysis
.
Clin J Am Soc Nephrol
.
2011
;
6
(
10
):
2364
73
.
22.
McMahon
GM
,
Preis
SR
,
Hwang
SJ
,
Fox
CS
.
Mid-adulthood risk factor profiles for CKD
.
J Am Soc Nephrol
.
2014
;
25
(
11
):
2633
41
.
23.
Lee
HS
.
Mechanisms and consequences of hypertriglyceridemia and cellular lipid accumulation in chronic kidney disease and metabolic syndrome
.
Histol Histopathol
.
2011
;
26
:
1599
610
.
24.
Vaziri
ND
,
Norris
K
.
Lipid disorders and their relevance to outcomes in chronic kidney disease
.
Blood Purif
.
2011
;
31
(
1–3
):
189
96
.
25.
Bowe
B
,
Xie
Y
,
Xian
H
,
Balasubramanian
S
,
Al-Aly
Z
.
Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression
.
Kidney Int
.
2016
;
89
(
4
):
886
96
.
26.
Kronenberg
F
.
HDL in CKD-the devil is in the detail
.
J Am Soc Nephrol
.
2018
;
29
(
5
):
1356
71
.
You do not currently have access to this content.